GoPath® Diagnostics Launches FDA-Cleared CGP Test under OncoTarget® 500 OncoTarget®500 genomic profiling identifies tumor-based somatic mutations with high accuracy and sensitivity – single nucleotide variants (SNVs), small insertions and deletions, amplifications, translocations, microsatellite instability (MSI) and tumor mutation burden (TMB). |